TELA Bio, Inc. (TELA)

USD 2.85

(3.26%)

Market Cap (In USD)

112.25 Million

Revenue (In USD)

58.45 Million

Net Income (In USD)

-46.66 Million

Avg. Volume

274.19 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.3-7.84
PE
-
EPS
-
Beta Value
0.968
ISIN
US8723811084
CUSIP
872381108
CIK
1561921
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Antony Koblish
Employee Count
-
Website
https://www.telabio.com
Ipo Date
2019-11-08
Details
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.